A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

William J. Gradishar, Virginia Kaklamani, Tarini P. Sahoo, Dasappa Lokanatha, Vinod Raina, Shailesh Bondarde, Minish Jain, Sunhee Kwon Ro, Nathalie A. Lokker, Lee Schwartzberg

Research output: Contribution to journal › Article › peer-review

85 Scopus citations

Fingerprint

Dive into the research topics of 'A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science